First-pass extracted concept

OPERA4

Candidate: toolkit itemType: multi component switch1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

OPERA4 variants

Extracted Explainers

What the tool is doing

OPERA4 is an optogenetically engineered AcrIIA4-derived switch that controls SpyCas9 activity in a light-dependent manner. The abstract states that it enables potent light-controllable genome editing in human cells as well.

Source 1DOI PubMed

Resources required

The reported design combines cpA4 with the LOV2 blue light sensory domain and uses dark-light switching to modulate activity.

Source 1DOI PubMed

What problem it solves

It solves the need for controllable, light-responsive inhibition of SpyCas9 for CRISPR applications.

Source 1DOI PubMed

Alternatives

The abstract identifies cpA4 as the immediate precursor scaffold, while the broader source context links OPERA4 to non-optogenetic Acr characterization and Acr-based control approaches.

Source 1DOI PubMed

Evidence Snippets

We further constructed a circularly permuted AcrIIA4 (cpA4) protein and developed optogenetically engineered, robust AcrIIA4 (OPERA4) variants by combining cpA4 with the light-oxygen-voltage 2 (LOV2) blue light sensory domain. OPERA4 variants are robust light-dependent tools for controlling the activity of SpyCas9 by approximately 1000-fold change under switching dark-light conditions in prokaryotes. OPERA4 variants can achieve potent light-controllable genome editing in human cells as well.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2023Nucleic Acids ResearchDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1applicationsupports2023Source 1DOI PubMed

OPERA4 variants can achieve potent light-controllable genome editing in human cells.

Quoted textsource-backed

OPERA4 variants can achieve potent light-controllable genome editing in human cells as well.

Claim 2engineering resultsupports2023Source 1DOI PubMed

OPERA4 variants were developed by combining circularly permuted AcrIIA4 with the LOV2 blue light sensory domain.

Quoted textsource-backed

developed optogenetically engineered, robust AcrIIA4 (OPERA4) variants by combining cpA4 with the light-oxygen-voltage 2 (LOV2) blue light sensory domain.

Claim 3performancesupports2023Source 1DOI PubMed

OPERA4 variants provide robust light-dependent control of SpyCas9 activity with approximately 1000-fold change under switching dark-light conditions in prokaryotes.

Quoted textsource-backed

OPERA4 variants are robust light-dependent tools for controlling the activity of SpyCas9 by approximately 1000-fold change under switching dark-light conditions in prokaryotes.